LG CNS is poised to enhance its digital healthcare portfolio through a strategic partnership with Cha Bio Group. The agreement, announced on January 15, will involve an investment of 10 billion won in Cha Biotech, the holding entity of Cha Bio Group, aiming to develop artificial intelligence (AI)-driven healthcare services and platforms.
The partnership was formalized in a ceremony held at the Cha Bio Complex in Pangyo, Seongnam, Gyeonggi Province, attended by Hyun Shinkyun, CEO of LG CNS, and Cha Wontae, Vice Chairman of Cha Bio Group, among other executives. This agreement encompasses not only financial investment but also collaborative efforts in AI transformation and digital transformation (AX·DX) initiatives.
Cha Bio Group is a multifaceted organization that includes hospitals, pharmaceuticals, bio research, and medical services. With subsidiaries such as Cha AI Healthcare, CMG Pharmaceutical, Cha Vaccine Institute, and others, the group operates healthcare facilities in South Korea as well as in international markets, including the United States, Singapore, Australia, and Japan.
As part of the agreement, LG CNS will establish a regular consultative body with Cha Bio Group to drive key AX·DX projects. In the immediate term, the companies plan to transition the group’s cloud infrastructure and establish a smart big data platform to consolidate various data sources. Additionally, they will enhance the infrastructure of therapeutic production facilities by integrating AI technology to streamline production processes.
In the longer term, LG CNS and Cha Bio Group will collaborate to commercialize “Connected Healthcare Services,” a strategic initiative that leverages specialized AI models. This service aims to analyze diverse health and lifestyle data generated from hospitals, residential spaces, and wearable devices. By utilizing healthcare-specific AI, the system will detect health risk signals and initiate automatic follow-up actions, which may include connecting with medical staff, offering medical guidance, and responding to emergencies.
To facilitate this initiative, LG CNS intends to employ “Exaone,” a lightweight large language model (sLLM) created by LG AI Research. This model will be instrumental in building a big data platform that effectively gathers and manages medical, genetic, and lifestyle data.
Both companies are also exploring the potential for global expansion of the Connected Healthcare Service, leveraging Cha Bio Group’s extensive network of overseas hospitals. They aim to utilize the data and insights gained from the platform to branch into related industries in the future.
A representative from LG CNS remarked, “We will strengthen our competitiveness in digital healthcare platforms through cooperation with Cha Bio Group,” further emphasizing their goal to become a leading technology partner driving AI and data-driven innovation within the healthcare sector.
See also
Bank of America Warns of Wage Concerns Amid AI Spending Surge
OpenAI Restructures Amid Record Losses, Eyes 2030 Vision
Global Spending on AI Data Centers Surpasses Oil Investments in 2025
Rigetti CEO Signals Caution with $11 Million Stock Sale Amid Quantum Surge
Investors Must Adapt to New Multipolar World Dynamics
